|
|
Volumn 27, Issue 3, 2012, Pages 279-
|
|
What are barriers to pharmacogenomics (PGx) clinical uptake?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABACAVIR;
AZATHIOPRINE;
FLUINDOSTATIN;
IRINOTECAN;
PRAVASTATIN;
STATIN;
TACROLIMUS;
WARFARIN;
ALLELE;
AREA UNDER THE CURVE;
DRUG COST;
DRUG LABELING;
DRUG METABOLISM;
DRUG MONITORING;
EDITORIAL;
GENETIC VARIABILITY;
GENOTYPE;
HEALTH INSURANCE;
HOMOZYGOSITY;
HUMAN;
MEDICAL EDUCATION;
PHARMACOGENOMICS;
PHENOTYPE;
POSTGRADUATE EDUCATION;
PRACTICE GUIDELINE;
PRESCRIPTION;
|
|
EID: 84863208488
PISSN: 13474367
EISSN: 18800920
Source Type: Journal
DOI: 10.2133/dmpk.DMPK-12-PF-903 Document Type: Editorial |
|
Times cited : (5)
|
|
References (0)
|
